ATTITUDES ON WARFARIN PHARMACOGENETIC TESTING IN CHINESE PATIENTS AND PUBLIC

被引:4
|
作者
Chan, Sze Ling [1 ]
Low, Joshua Jun Wen [2 ]
Chia, Kee Seng [1 ,3 ,4 ,5 ,6 ]
Wee, Hwee-Lin [2 ,7 ]
机构
[1] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore
[2] Natl Univ Singapore, Dept Pharm, Singapore 117548, Singapore
[3] Natl Univ Singapore, Ctr Mol Epidemiol, Singapore 117548, Singapore
[4] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[5] Genome Inst Singapore, Singapore, Singapore
[6] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore
[7] Singapore Gen Hosp, Dept Rheumatol & Immunol, Singapore, Singapore
关键词
Warfarin; Pharmacogenetic testing; Attitudes; Asian; ADVERSE DRUG-REACTIONS;
D O I
10.1017/S026646231300069X
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: Genetic factors affecting warfarin maintenance dose have been well established, but patient acceptance is a necessary consideration for the successful clinical implementation of warfarin pharmacogenetic testing (WPGT). In this study, we aimed to determine the attitudes toward WPGT among Singaporean Chinese. Methods: A total of 194 warfarin patients and 187 members of the public completed a structured survey on paper and the Internet, respectively. Attitudes were expressed as willingness to undergo WPGT (single item with 5-point response) and expectations and concerns about WPGT (two multi-item scales). Relationships between attitudes and socio-demographic and clinical variables were explored using Fisher's exact test, Student's t-test, one-way analysis of variance or Pearson's correlation. Results: Majority of respondents were willing to or neutral about undergoing WPGT. Both patients and public had relatively high expectations (mean [SD]: 3.77 [0.63], and 3.97 [0.55], respectively) and moderately high concerns (mean [SD]: 3.30 [0.69] and 3.33 [0.68], respectively) about WPGT. Willingness to undergo WPGT was associated with gender, educational status, length of warfarin treatment, and number of chronic diseases among warfarin patients, and with history of adverse drug reactions and number of chronic diseases among the public. Higher expectation of WPGT was associated with higher willingness (p < .001 in both populations), while higher concern was associated with lower willingness to undergo WPGT among the public (p = .004) but not among patients (p = .072). Conclusion: Patient acceptance is not a major barrier to clinical implementation of WPGT but patient education is necessary and the ethical, social, and legal issues should be addressed.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 50 条
  • [1] Willingness-to-pay and preferences for warfarin pharmacogenetic testing in Chinese warfarin patients and the Chinese general public
    Chan, Sze Ling
    Low, Joshua Jun Wen
    Lim, Yee Wei
    Finkelstein, Eric
    Farooqui, Muhammad Assad
    Chia, Kee Seng
    Wee, Hwee Lin
    PERSONALIZED MEDICINE, 2013, 10 (02) : 127 - 137
  • [2] Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients
    Liu, Yu
    Yang, Jie
    Xu, Qiang
    Xu, Bin
    Gao, Lei
    Zhang, Yuxiao
    Zhang, Yan
    Wang, Hongjuan
    Lu, Caiyi
    Zhao, Yusheng
    Yin, Tong
    THROMBOSIS RESEARCH, 2012, 130 (03) : 435 - 440
  • [3] Survey of US public attitudes toward pharmacogenetic testing
    S B Haga
    J M O'Daniel
    G M Tindall
    I R Lipkus
    R Agans
    The Pharmacogenomics Journal, 2012, 12 : 197 - 204
  • [4] Survey of US public attitudes toward pharmacogenetic testing
    Haga, S. B.
    O'Daniel, J. M.
    Tindall, G. M.
    Lipkus, I. R.
    Agans, R.
    PHARMACOGENOMICS JOURNAL, 2012, 12 (03): : 197 - 204
  • [5] Implications of Pharmacogenetic Testing for Patients Taking Warfarin or Clopidogrel
    Megan M. Donohue
    David L. Tirschwell
    Current Neurology and Neuroscience Reports, 2011, 11 : 52 - 60
  • [6] Implications of Pharmacogenetic Testing for Patients Taking Warfarin or Clopidogrel
    Donohue, Megan M.
    Tirschwell, David L.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2011, 11 (01) : 52 - 60
  • [7] Pharmacogenetic Testing for Warfarin Sensitivity
    Lyon, Elaine
    McMillin, Gwen
    Melis, Roberta
    CLINICS IN LABORATORY MEDICINE, 2008, 28 (04) : 525 - 537
  • [8] Validation of warfarin pharmacogenetic algorithms in 586 Han Chinese patients
    Peng, Qi
    Huang, Shujun
    Chen, Xiaoying
    Yuan, Yayan
    Yu, Yajun
    Tao, Liang
    Zhang, Zhenlu
    Xu, Mousheng
    PHARMACOGENOMICS, 2015, 16 (13) : 1465 - 1474
  • [9] Comparative performance of different warfarin pharmacogenetic algorithms in Chinese patients
    Lou, Ying
    Liu, Hong
    Han, Lulu
    Huang, Yiling
    Li, Yishi
    CARDIOLOGY, 2013, 126 : 139 - 139
  • [10] Chinese Patients With Heart Valve Replacement Do Not Benefit From Warfarin Pharmacogenetic Testing on Anticoagulation Outcomes
    Hao, Yexia
    Yang, Jun
    Zheng, Xuan
    Hu, Yuanping
    Yan, Xinsheng
    Zhang, Litao
    THERAPEUTIC DRUG MONITORING, 2019, 41 (06) : 748 - 754